Picard Medical Securities Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 14 2026
0mins
Should l Buy PMI?
Source: Globenewswire
- Class Action Timeline: The class action period for Picard Medical, Inc. (NYSE American: PMI) securities runs from September 2, 2025, to October 31, 2025, with a lead plaintiff application deadline set for April 13, 2026, allowing investors to represent others in the litigation.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements and failed to disclose significant adverse facts regarding its business and securities trading, which resulted in investor losses and damaged the company's market reputation.
- Choosing Legal Counsel: Investors are encouraged to select qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal support and resources in the class action.
- Historical Performance: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and was ranked as a leading firm in securities class actions in 2017, demonstrating its expertise and success in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Picard Medical in the Northern District of California on behalf of investors who purchased securities between September 2 and October 31, 2025, indicating significant legal risks for the company.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, reflecting extreme market concerns regarding the company's financial health.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, leading to substantial investor losses and highlighting severe deficiencies in corporate governance and transparency.
- Investor Rights Protection: Investors must apply by April 3, 2026, to be appointed as lead plaintiffs, demonstrating the law firm's commitment to protecting investor rights, which may influence future litigation strategies and the company's reputation.
See More
Picard Medical Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and operations during the securities trading period, misleading investors and impacting their decision-making.
- Fraudulent Activities Exposed: Specific allegations include involvement in a fraudulent stock promotion scheme through social media misinformation and insiders using offshore accounts to manipulate stock prices, severely harming investor interests.
- Law Firm's Expertise: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capabilities and resource advantages in handling such cases.
See More
Reminder of Class Action Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and raising serious concerns about the company's financial health.
- False Promotion Exposed: Investigations revealed that Picard's stock was the target of an illicit social media promotion scheme, where impersonators of real financial advisors falsely touted the stock in online forums and social media, artificially inflating its price and harming investors' interests.
- Lawsuit Allegations: The class action lawsuit alleges that throughout the Class Period, the company failed to disclose material adverse facts regarding its business, operations, and prospects, specifically that it was affected by a fraudulent stock promotion scheme, misleading investors about its true condition.
- Investor Action Deadline: Investors must file a motion by April 3, 2026, to request appointment as lead plaintiff in this class action lawsuit to recover losses incurred due to false information, underscoring the importance of timely legal action.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 2 and October 31, 2025, with a deadline to contact the firm by April 3, 2026.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements during the class period, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in significant losses for investors once the truth was revealed.
- Legal Representation Information: The Schall Law Firm offers free consultations to affected investors, encouraging them to reach out before class certification to ensure their rights are protected, as failing to act may result in being an absent class member and losing the chance to claim damages.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally and emphasizing its expertise and experience in securities law to assist investors in recovering their losses.
See More
Faruqi & Faruqi Investigates Securities Claims Against Picard Medical
- Legal Claims Investigation: Faruq & Faruqi is investigating potential claims against Picard Medical, specifically targeting investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding the situation.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is set for April 13, 2026, urging investors to act promptly to protect their rights.
- Stock Exchange Listing: Picard Medical is listed on the New York Stock Exchange (NYSE:PMI), and this investigation may negatively impact its stock price, prompting investors to monitor developments closely to assess potential risks.
See More
Class Action Notice for Picard Medical Securities Purchasers
- Class Action Deadline: The lead plaintiff deadline for the Picard Medical securities class action is April 13, 2026, requiring investors to apply by this date to represent other investors and protect their rights in the litigation.
- No Upfront Costs: Investors joining the class action incur no upfront fees or costs, as attorney fees will be covered through a contingency fee arrangement, reducing the financial burden on investors and encouraging broader participation from affected parties.
- False Statement Allegations: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and operations during the securities trading period, including a fraudulent stock promotion scheme involving social media, which may have led to investor losses.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, prompting investors to carefully consider the qualifications and track record of their legal counsel.
See More
Class Action Lawsuit Filed Against Picard Medical, Inc.
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Picard Medical in the Northern District of California on behalf of investors who purchased securities between September 2 and October 31, 2025, indicating significant legal risks for the company.
- Stock Price Crash: On October 24, 2025, Picard's stock price plummeted by 70%, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, reflecting extreme market concerns regarding the company's financial health.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, leading to substantial investor losses and highlighting severe deficiencies in corporate governance and transparency.
- Investor Rights Protection: Investors must apply by April 3, 2026, to be appointed as lead plaintiffs, demonstrating the law firm's commitment to protecting investor rights, which may influence future litigation strategies and the company's reputation.
See More
Picard Medical Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Picard Medical (NYSE: PMI) securities between September 2 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Picard Medical's management failed to disclose significant adverse facts regarding the company's business and operations during the securities trading period, misleading investors and impacting their decision-making.
- Fraudulent Activities Exposed: Specific allegations include involvement in a fraudulent stock promotion scheme through social media misinformation and insiders using offshore accounts to manipulate stock prices, severely harming investor interests.
- Law Firm's Expertise: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capabilities and resource advantages in handling such cases.
See More
Reminder of Class Action Lawsuit for Picard Medical Investors
- Stock Price Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, dropping from $13.20 to $3.99 per share, resulting in significant losses for investors and raising serious concerns about the company's financial health.
- False Promotion Exposed: Investigations revealed that Picard's stock was the target of an illicit social media promotion scheme, where impersonators of real financial advisors falsely touted the stock in online forums and social media, artificially inflating its price and harming investors' interests.
- Lawsuit Allegations: The class action lawsuit alleges that throughout the Class Period, the company failed to disclose material adverse facts regarding its business, operations, and prospects, specifically that it was affected by a fraudulent stock promotion scheme, misleading investors about its true condition.
- Investor Action Deadline: Investors must file a motion by April 3, 2026, to request appointment as lead plaintiff in this class action lawsuit to recover losses incurred due to false information, underscoring the importance of timely legal action.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between September 2 and October 31, 2025, with a deadline to contact the firm by April 3, 2026.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements during the class period, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in significant losses for investors once the truth was revealed.
- Legal Representation Information: The Schall Law Firm offers free consultations to affected investors, encouraging them to reach out before class certification to ensure their rights are protected, as failing to act may result in being an absent class member and losing the chance to claim damages.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally and emphasizing its expertise and experience in securities law to assist investors in recovering their losses.
See More
Faruqi & Faruqi Investigates Securities Claims Against Picard Medical
- Legal Claims Investigation: Faruq & Faruqi is investigating potential claims against Picard Medical, specifically targeting investors who purchased securities between September 2, 2025, and October 31, 2025, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding the situation.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is set for April 13, 2026, urging investors to act promptly to protect their rights.
- Stock Exchange Listing: Picard Medical is listed on the New York Stock Exchange (NYSE:PMI), and this investigation may negatively impact its stock price, prompting investors to monitor developments closely to assess potential risks.
See More
Class Action Notice for Picard Medical Securities Purchasers
- Class Action Deadline: The lead plaintiff deadline for the Picard Medical securities class action is April 13, 2026, requiring investors to apply by this date to represent other investors and protect their rights in the litigation.
- No Upfront Costs: Investors joining the class action incur no upfront fees or costs, as attorney fees will be covered through a contingency fee arrangement, reducing the financial burden on investors and encouraging broader participation from affected parties.
- False Statement Allegations: The lawsuit alleges that Picard Medical failed to disclose significant adverse facts related to its business and operations during the securities trading period, including a fraudulent stock promotion scheme involving social media, which may have led to investor losses.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases, prompting investors to carefully consider the qualifications and track record of their legal counsel.
See More
